Ph 3 KEYNOTE-B96 Trial Met Primary PFS Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers May 21, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer patients May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer May 6, 2025
Clinical development of nemvaleukin to discontinue following review of data from Ph 2 ARTISTRY-6 and Ph 3 ARTISTRY-7 trials April 22, 2025
SON-1010 + Atezolizumab combo Demonstrates a Strong Safety Profile in Platinum-Resistant Ovarian Cancer patients April 15, 2025
SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer April 8, 2025
FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS April 2, 2025
Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer April 2, 2025
Ph 3 Study Design Finalized with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer April 2, 2025
SGO 2025: ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients March 18, 2025
SGO 2025: Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC announced March 18, 2025
SGO 2025: Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer Presented March 18, 2025
SGO 2025: Rinatabart Sesutecan (Rina-S) Shows Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer March 18, 2025
Translational Data Announced from Ph 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 25, 2025
FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer February 19, 2025
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T) for Advanced Ovarian Cancer February 11, 2025
Ongoing Ph 2 trial expanded to optimize stenoparib dose and refine DRP® patient selection criteria February 10, 2025
Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer February 4, 2025
FDA Acceptance and Priority Review of NDA for Avutometinib + Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Announced January 7, 2025
